![]() Hexavac was not returned to the market after the suspension was lifted for commercial reasons, according to the vaccines joint venture, and its marketing authorisation was officially withdrawn last year. Infanrix Hexa has been on the market since 2000 and has had the hexavalent paediatric vaccine category to itself since 2005, when a European Commission review of short and long-term protection afforded by recombinant hepatitis B vaccines led to the temporary suspension of Sanofi Pasteur MSD's rival Hexavac product. Hexyon/Hexacima can be used for primary and booster vaccinations from the age of six weeks and comes onto the market as a competitor to GlaxoSmithKline's Infanrix Hexa, part of the pharma company's Infanrix/Pediarix range which made around £775m ($1.18bn) in sales last year. Olivier Charmeil, chief executive of Sanofi Pasteur, said the therapy "will raise the standard of care of vaccination for millions of children", adding that it will be an "important growth driver" for the company in 2013 and beyond. The new vaccine will be sold as Hexyon in western European countries by the firm's joint venture with Merck Sharp and Dohme – Sanofi Pasteur MSD – and under the brand name Hexacima in eastern European by Sanofi Pasteur. ![]() Hexyon/Hexacima is the only full liquid, ready-to-use vaccine of its type on the EU market, according to Sanofi Pasteur, and provides protection against diphtheria, tetanus and pertussis (DTP) as well as hepatitis B, polio and Haemophilus influenzae type B (Hib), a cause of meningitis. The European Commission (EC) has approved a six-in-one (hexavalent) paediatric vaccine developed by the Sanofi Pasteur MSD joint venture.
0 Comments
Leave a Reply. |